Forest Laboratories files cariprazine NDA for two indications

Forest Laboratories has submitted an NDA to the FDA for cariprazine, an orally active and potent dopamine D3-preferring D3/D2 receptor partial agonist. Cariprazine was discovered by Hungary-based Gedeon Richter and is licensed to Forest Laboratories in the US and Canada.

The application for the treatment of schizophrenia includes results from three positive trials in over 1,700 patients, two fixed dose studies with active controls and one fixed flexible placebo-controlled dose study using the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score as primary efficacy endpoint. The application for the acute treatment of manic or mixed episodes associated with bipolar I disorder includes results from three positive placebo-controlled trials in over 1,000 patients, two flexible dose studies and one fixed flexible-dose study using the change from baseline in the Young Mania Rating Scale (YMRS) total score as primary efficacy endpoint.

In the schizophrenia and bipolar mania pivotal trials, cariprazine was generally well tolerated. The most commonly reported adverse reactions (>= 5 per cent and twice placebo), which were predominantly mild-to-moderate in severity, were akathisia, extrapyramidal disorder, dyspepsia, restlessness, tremor, fatigue and vomiting.

Forest Laboratories files cariprazine NDA for two indications

Forest Laboratories has submitted an NDA to the FDA for cariprazine, an orally active and potent dopamine D3-preferring D3/D2 receptor partial agonist. Cariprazine was discovered by Hungary-based Gedeon Richter and is licensed to Forest Laboratories in the US and Canada.

The application for the treatment of schizophrenia includes results from three positive trials in over 1,700 patients, two fixed dose studies with active controls and one fixed flexible placebo-controlled dose study using the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score as primary efficacy endpoint. The application for the acute treatment of manic or mixed episodes associated with bipolar I disorder includes results from three positive placebo-controlled trials in over 1,000 patients, two flexible dose studies and one fixed flexible-dose study using the change from baseline in the Young Mania Rating Scale (YMRS) total score as primary efficacy endpoint.

In the schizophrenia and bipolar mania pivotal trials, cariprazine was generally well tolerated. The most commonly reported adverse reactions (>= 5 per cent and twice placebo), which were predominantly mild-to-moderate in severity, were akathisia, extrapyramidal disorder, dyspepsia, restlessness, tremor, fatigue and vomiting.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.